Clinical trial · Interventional
Autologous Bone Marrow Transplantation in Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
Autologous Bone Marrow Transplantation for Acute Non-Lymphoblastic Leukemia During First or Subsequent Remission
NCT00186381CI-TRIAL-00003711completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluate the role of high dose chemotherapy with autologous hematopoietic cell transplantation for AML.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| high dose chemotherapy then autologous hematopoietic cell transplant | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Disease free survival (DFS)
Secondary outcomes (4)
- measure
- Transplant related mortality (TRM)
- measure
- Toxicity
- measure
- Adequacy of cell collections
- measure
- Engraftment kinetics
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Inclusion Criteria:- must be in remission * adequate organ function Exclusion Criteria:- prior MDS * active infection * liver disease
References
Publications (0)
Data not yet available
No reference posted for this study.